NCT06544109View on ClinicalTrials.gov

Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients

PHASE2/PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

August 1, 2025

Study Completion Date

August 1, 2028

Conditions
Acute Promyelocytic Leukemia
Interventions
DRUG

venetoclax

patients in whom the WBC counts increased to more than 2 × 109/L received Venetoclax

Trial Locations (1)

215006

Qiu huiying, Suzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER